News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

With Johnson & Johnson (JNJ)’s Help, Vedanta Marches Ahead With Microbiome Drug Cocktail


7/3/2013 6:23:20 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

When Johnson & Johnson (NYSE: JNJ) announced it opened its Boston Innovation Center, it snuck in an unspecified investment in a PureTech Ventures-backed startup named Vedanta BioSciences. And while the exact nature of the relationship is unclear, one thing is for sure: the Cambridge, MA-based startup now has some big muscle behind it to help move its first drug into clinical trials.

Help employers find you! Check out all the jobs and post your resume.

Read at Xconomy

comments powered by Disqus
Xconomy
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES